Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma

NCT01321437 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT01321437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
December 31, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma, stage iiia melanoma, stage iiib melanoma, stage iiic melanoma